Sean M Dawes1, Sheena Tsai2, Haley Gittleman3, Jill S Barnholtz-Sloan4, Jeremy S Bordeaux5. 1. Michigan State University College of Osteopathic Medicine, East Lansing, Michigan. 2. Case Western Reserve University School of Medicine, Cleveland, Ohio. 3. Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio. 4. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio; Case Western Reserve University School of Medicine, Cleveland, Ohio. 5. Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio. Electronic address: jeremy.bordeaux@uhhospitals.org.
Abstract
BACKGROUND: Melanoma is a cutaneous malignancy common in the white population but can also occur in other racial groups. OBJECTIVE: We sought to evaluate survival across racial groups in patients given a diagnosis of malignant melanoma. METHODS: The Surveillance, Epidemiology, and End Results database was used to populate a cohort of 96,953 patients given a diagnosis of cutaneous melanoma as their primary cancer, from 1992 to 2009. RESULTS: White patients had the longest survival time (P < .05), followed by Hispanic (P < .05), Asian American/Native American/Pacific Islander (P < .05), and black (P < .05) patients, respectively. Survival stratified by race and stage showed that for stages I and III, blacks had a significantly lower survival (P < .05), and increased hazard ratios (stage I hazard ratio, 3.037 [95% confidence interval, 2.335-3.951]; stage III hazard ratio, 1.864 [95% confidence interval, 1.211-2.87]). The proportion of later stage cutaneous melanoma (stages II-IV) was greater in blacks compared with whites. CONCLUSION: Despite higher incidence of cutaneous melanoma in whites, overall survival for cutaneous melanoma in non-whites was significantly lower. Our results suggest that more emphasis is needed for melanoma screening and awareness in non-white populations to improve survival outcomes.
BACKGROUND:Melanoma is a cutaneous malignancy common in the white population but can also occur in other racial groups. OBJECTIVE: We sought to evaluate survival across racial groups in patients given a diagnosis of malignant melanoma. METHODS: The Surveillance, Epidemiology, and End Results database was used to populate a cohort of 96,953 patients given a diagnosis of cutaneous melanoma as their primary cancer, from 1992 to 2009. RESULTS: White patients had the longest survival time (P < .05), followed by Hispanic (P < .05), Asian American/Native American/Pacific Islander (P < .05), and black (P < .05) patients, respectively. Survival stratified by race and stage showed that for stages I and III, blacks had a significantly lower survival (P < .05), and increased hazard ratios (stage I hazard ratio, 3.037 [95% confidence interval, 2.335-3.951]; stage III hazard ratio, 1.864 [95% confidence interval, 1.211-2.87]). The proportion of later stage cutaneous melanoma (stages II-IV) was greater in blacks compared with whites. CONCLUSION: Despite higher incidence of cutaneous melanoma in whites, overall survival for cutaneous melanoma in non-whites was significantly lower. Our results suggest that more emphasis is needed for melanoma screening and awareness in non-white populations to improve survival outcomes.
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Raghav Tripathi; Konrad D Knusel; Harib H Ezaldein; Jeffrey F Scott; Jeremy S Bordeaux Journal: JAMA Dermatol Date: 2018-11-01 Impact factor: 10.282
Authors: Kimberly A Miller; Sarah E Piombo; Junhan Cho; Shauna Higgins; Ashley Wysong; Steve Sussman; Myles G Cockburn; Adam M Leventhal Journal: J Invest Dermatol Date: 2018-02-23 Impact factor: 8.551